Table 2.
The correlation between CCNY mRNA expression and clinicopathologic features of HCC patients.
| Clinicopathologic features | N | CCNY mRNA level | P-value |
|---|---|---|---|
| Age | |||
| ≤50 | 28 | 3.68±0.73 | 0.307 |
| >50 | 27 | 3.46±0.85 | |
| Gender | |||
| Male | 39 | 3.60±0.79 | 0.675 |
| Female | 16 | 3.50±0.82 | |
| Pathological types | |||
| Hepatocellular type | 44 | 3.58±0.79 | 0.728 |
| Cholangiocarcinoma type | 5 | 3.34±0.67 | |
| Mixed cell type | 6 | 3.71±0.75 | |
| Tumor size | |||
| ≤5 cm | 13 | 3.21±0.65 | 0.038* |
| >5 cm | 42 | 3.68±0.71 | |
| Tumor invasion | |||
| T1+T2 | 17 | 3.30±0.56 | 0.030* |
| T3+T4 | 38 | 3.75±0.74 | |
| Lymph node metastasis | |||
| N0 | 37 | 3.41±0.70 | 0.041* |
| N+ | 18 | 3.87±0.88 | |
| Clinic stages | |||
| I–II | 31 | 3.65±0.84 | 0.406 |
| III–IV | 24 | 3.47±0.72 | |
| Histological grade | |||
| I+II | 33 | 3.40±0.63 | 0.035* |
| III+IV | 22 | 3.83±0.84 | |
HCC – hepatocellular carcinoma; CCNY – Cyclin Y;
*
P-value significant differences.